ALX Oncology Holdings Investor Relations Material
Latest events
Status Update
ALX Oncology Holdings
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ALX Oncology Holdings Inc
Access all reports
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that target the CD47 checkpoint pathway, which plays a critical role in cancer cells' ability to evade the immune system. The company's lead product candidate, evorpacept, is designed to block CD47 and is being developed in combination with other anti-cancer agents. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for ALX Oncology Holdings Inc
Status Update
ALX Oncology Holdings Inc
Status Update
ALX Oncology Holdings Inc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ALXO
Country
🇺🇸 United States